Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-02-21 @ 9:03 AM
Study NCT ID:
NCT02158858
Status:
COMPLETED
Last Update Posted:
2025-10-08
First Post:
2014-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Sponsor:
Constellation Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myelofibrosis | View |
| None | Leukemia, Myelocytic, Acute | View |
| None | Myelodysplastic/Myeloproliferative Neoplasm | View |
| None | Myelodysplastic Syndrome (MDS) | View |
| None | Preleukemia | View |
| None | Primary Myelofibrosis | View |
| None | Myeloproliferative Disorders | View |
| None | Bone Marrow Disease | View |
| None | Hematological Disease | View |
| None | Precancerous Conditions | View |
| None | Neoplasms | View |
| None | Leukemia | View |
| None | Neoplasms by Histologic Type | View |
| None | Essential Thrombocytosis | View |